Weekly paclitaxel in the adjuvant treatment of breast cancer.

The New England Journal of Medicine
Joseph A SparanoNancy E Davidson

Abstract

We compared the efficacy of two different taxanes, docetaxel and paclitaxel, given either weekly or every 3 weeks, in the adjuvant treatment of breast cancer. We enrolled 4950 women with axillary lymph node-positive or high-risk, lymph node-negative breast cancer. After randomization, all patients first received 4 cycles of intravenous doxorubicin and cyclophosphamide at 3-week intervals and were then assigned to intravenous paclitaxel or docetaxel given at 3-week intervals for 4 cycles or at 1-week intervals for 12 cycles. The primary end point was disease-free survival. As compared with patients receiving standard therapy (paclitaxel every 3 weeks), the odds ratio for disease-free survival was 1.27 among those receiving weekly paclitaxel (P=0.006), 1.23 among those receiving docetaxel every 3 weeks (P=0.02), and 1.09 among those receiving weekly docetaxel (P=0.29) (with an odds ratio >1 favoring the groups receiving experimental therapy). As compared with standard therapy, weekly paclitaxel was also associated with improved survival (odds ratio, 1.32; P=0.01). An exploratory analysis of a subgroup of patients whose tumors expressed no human epidermal growth factor receptor type 2 protein found similar improvements in disease-...Continue Reading

References

Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I Craig HendersonLarry Norton
May 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eleftherios P MamounasNorman Wolmark
Jun 3, 2005·The New England Journal of Medicine·Miguel MartinUNKNOWN Breast Cancer International Research Group 001 Investigators
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S E JonesP M Ravdin
Apr 13, 2006·JAMA : the Journal of the American Medical Association·Donald A BerryEric P Winer
Sep 30, 2006·European Urology·Fabio Calabrò, Cora N Sternberg
May 22, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Clifford A HudisJo Anne Zujewski
Oct 12, 2007·The New England Journal of Medicine·Daniel F HayesUNKNOWN Cancer and Leukemia Group B (CALGB) Investigators

❮ Previous
Next ❯

Citations

Sep 22, 2009·Cancer Chemotherapy and Pharmacology·Norikazu MasudaJunichi Sakamoto
Dec 25, 2010·Cancer Chemotherapy and Pharmacology·M TaharaM Tsukuda
Mar 5, 2011·Cancer Chemotherapy and Pharmacology·Lakshmi RajdevJoseph A Sparano
Dec 18, 2008·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Katsumasa KuroiFrederick H Hausheer
Feb 3, 2009·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Lincy S LalWilliam Dana
Nov 18, 2011·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Michael J BergerCharles L Shapiro
May 16, 2012·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Kojiro ShimozumaFrederick H Hausheer
May 21, 2013·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Ming J PoiRobert Wesolowski
Nov 23, 2011·International Journal of Clinical Oncology·Yuko TanabeYasuhiro Fujiwara
Feb 26, 2011·Breast Cancer Research and Treatment·Roisin M ConnollyAntonio C Wolff
Apr 25, 2012·Breast Cancer Research and Treatment·Daniel L HertzE Claire Dees
May 9, 2012·Breast Cancer Research and Treatment·Saroj NiraulaPamela J Goodwin
Nov 10, 2012·Breast Cancer Research and Treatment·Allison W KurianScarlett L Gomez
Feb 21, 2013·Breast Cancer Research and Treatment·Miguel MartínPhilip S Bernard
Sep 27, 2012·Journal of Mammary Gland Biology and Neoplasia·Elizabeth ComenLarry Norton
Apr 11, 2009·Current Treatment Options in Oncology·Mary LeungDaniel R Budman
Nov 4, 2011·Current Treatment Options in Oncology·Christos Vaklavas, Andres Forero-Torres
Oct 16, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Carmen FríasMiguel Ángel Casado
Jul 22, 2011·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Jordi GinésMiguel A Casado
Oct 1, 2013·The Breast : Official Journal of the European Society of Mastology·Harold J Burstein
Sep 3, 2008·Nature Clinical Practice. Oncology·Linda Vahdat
Dec 10, 2009·Nature Reviews. Clinical Oncology·Philippe L BedardMartine J Piccart-Gebhart
Feb 2, 2010·Nature Reviews. Clinical Oncology·Eitan AmirBostjan Seruga
Feb 4, 2010·Nature Reviews. Clinical Oncology·Serena Di Cosimo, José Baselga
Dec 1, 2010·Nature Reviews. Clinical Oncology·Patrick G Morris, Clifford A Hudis
Jul 19, 2008·The New England Journal of Medicine·Masaharu TsubokuraTsunehiko Komatsu
Dec 3, 2010·The New England Journal of Medicine·Miguel MartínUNKNOWN GEICAM 9805 Investigators
Feb 17, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G FrasciG D'Aiuto
Jul 23, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B LeyssensI Mombaerts
Nov 11, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·O GluzN Harbeck
Mar 10, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·X S ChenK W Shen
May 25, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·K ShitaraK Muro

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Marjorie C GreenGabriel N Hortobagyi
© 2022 Meta ULC. All rights reserved